Biweekly THP-COPBLM including pirarubicin (THP), which is thought to be less toxic than doxorubicin, was used to treat non-Hodgkin's lymphoma (NHL) and the remission rate and adverse events were studied in 42 patients younger than 69 years. Complete remission (CR) was achieved in 37 patients (88.1%) and partial remission in five ( 
Introduction
In recent years, non-Hodgkin's lymphoma (NHL) has been treated successfully in an increasing number of patients. Third-generation chemotherapy has achieved complete remission in 80-85% of the patients treated, and long-term survival in 60-70%. 1, 2 According to Fisher et al, 3 however, intensified chemotherapy with third-generation multiple anticancer agents is not significantly different in efficacy from the CHOP regimen, but it causes more adverse effects. When patients treated mainly with the CHOP regimen were classified into prognostic groups according to the international prognostic index, 4 the 5-year survival rate was 73% for the low-risk group, while the rates for the low-intermediate (L-I), high-intermediate (H-I), and high (H)-risk groups were 51, 43 and 26%, respectively. This indicates that the CHOP regimen is satisfactorily effective for low-risk group non-Hodgkin's lymphoma, but is inadequate when the prognosis is poorer. In order to improve the effectiveness of chemotherapy for these poorer prognostic groups, a biweekly dose-intensified CHOP regimen has been used, in which CHOP is administered with G-CSF to increase the doses of the key agents (cyclophosphamide (CPA) and doxorubicin (DXR)). 5, 6 The total dose of DXR is limited by cardiotoxicity. When given alone, the dose limit is 450-550 mg/m 2 . Our previous study showed that cardiotoxicity appeared when the total dose of DXR in the COP-BLAM regimen was 350-400 mg/m. 2, 7 If it is remembered that 40-50% of patients with NHL can usually achieve long-term survival, cardiotoxicity associated with prolonged administration of DXR should be considered. When Correspondence: N Niitsu; Fax: +81 03 3763 8298 Received 23 March 1998; accepted 27 May 1998 relapse and refractory NHL is treated by high-dose chemotherapy with peripheral blood stem cell transplantation (PBSCT), decreased cardiac function also not infrequently poses a problem.
In the present study, we used a biweekly THP-COPBLM regimen including a new anthracycline anticancer agent, pirarubicin (THP), which is considered to be less cardiotoxic than DXR, to increase the dose intensity, and we assessed the efficacy and occurrence of adverse events.
Patients and methods

Patients
Forty-two Japanese patients with previously untreated NHL who received combination therapy between April 1994 and August 1997 are included in this report. The median age was 56 years (range 18-69). There were 24 males and 18 females. According to the Ann Arbor classification, 8 staging was determined by bone marrow aspiration, bone marrow biopsy, computerized tomography (CT) of the chest, abdominal sonography, abdominal CT, gastrointestinal endoscopy and gallium scintigraphy as well as routine examinations. Their performance status (PS) was between 0 and 3 according to the Eastern Cooperative Oncology Group (ECOG). 9 Of the 42 patients, 12 had stage II, 17 had stage III and 13 had stage IV. Histopathology of the NHLs was classified according to the Working formulation. 10 They were of the diffuse large cell type in 22 patients, the diffuse mixed cell type in 15, the diffuse small non-cleaved cell type in three, and the follicular large cell type in two. All patients tested negative for human T cell lymphotropic virus type-I (HTLV-I) antibody. The score system of the International Non-Hodgkin's Lymphoma Prognostic Factors (INHLPF) Project 4 was used to evaluate therapeutic effects by age-adjusted risk group. The three prognostic factors employed were: Ann Arbor stages III and IV, a PS score of 2 or higher as determined according to the ECOG criteria, and an increased lactate dehydrogenase (LDH) level. They were of the L-I risk group in 17, the H-I group risk in 16, and the H risk group in nine. 2 on days 1-7 and bleomycin 10 mg on day 10 for six cycles every 2 weeks if absolute neutrophil count (ANC) was у2 × 10 9 /l and platelets у10 × 10 9 /l. Dose modification was planned for CPA and THP as follows: decrease of 25% if ANC count was Ͻ2 × 10 9 /l or platelet count Ͻ100 × 10 9 /l on the planned day of treatment; decrease of 50% if the leukocyte count was Ͻ1.5 × 10 9 /l or platelet count Ͻ70 × 10 9 /l; and chemotherapy delay until hematologic recovery if the leukocyte count was Ͻ1 × 10 9 /l or platelet count Ͻ50 × 10 9 /l. Doses were not adjusted for patient's age. G-CSF (lenograstim) was administered as a daily subcutaneous dose of 2 g/kg from day 5 up to day 13 without day 10 or ANC Ͼ5 × 10 9 /l.
Analysis and statistics
Response to treatment was documented on completion of chemotherapy. Complete remission (CR) was defined as absence of detectable disease on clinical, radiologic and histologic criteria. Partial remission (PR) required a Ͼ50% reduction of tumor volume. Duration of CR was calculated from completion of chemotherapy to relapse or last followup. Overall survival (OS) was the interval from initiation of therapy to the time of death or last follow-up. Survival analysis was performed according to Kaplan-Meier. 11 The generalized Wilcoxon test (rank sum test) was used to compare mean difference between the two groups. A level of P Ͻ 0.05 was accepted as statistically significant. WHO criteria 12 were used to define adverse events. Dose intensity (DI) was evaluated according to Hryniuk and Bush. 13 The actual DI of CPA, THP were calculated by dividing the actual total amount of each drug by the time needed for delivery. The expressions of the actual DI as fractions of the stated protocol dosages were defined as relative DI. The calculation was made for the whole treatment course and separately for the initial cycles needed to achieve maximal response (either CR or maximal degree of partial remission) or to determine the progression of disease.
Results
Therapeutic effects
All patients were evaluated for response and survival. Of the 42 patients treated, 37 (88.1%) achieved a CR and five (11.9%) achieved a PR, for a response rate of 100%. The response rate was 100% for stage II disease and 83.3% for stage III and IV disease. With respect to histopathology, the response rate was 95.5% for diffuse large cell type, 80% for diffuse mixed cell type, 66.7% for diffuse small non-cleaved cell type and 100% for follicular large cell type, with no significant difference observed among histologic subsets. The CR rate for patients with bone marrow involvement was 40%, that for patients with bulky masses of 10 cm or greater in diameter was 50%, and soluble interleukin-2 receptor level Ͼ1000 U/ml was 64.3%. These rates were somewhat lower than the overall rate. According to the INHLPF (age-adjusted (AAII)) index, L-I risk was 94.1%, H-I risk 87.1% and H risk 77.8% (Table 1 ). The 3-year overall survival and event-free survival were 72.1% and 58%, respectively (Figure 1 ). According to the INHLPF index, the 42 patients were divided into the three risk groups. There was no significant difference in the survival and event-free survival among the three groups (log-rank, Wilcoxon test) (Figure 2 ). 
Figure 1
Survival time and event-free survival of non-Hodgkin's lymphoma patients treated with biweekly THP-COPBLAM therapy.
Figure 2
Survival time and event-free survival by the International Non-Hodgkin's Lymphoma Prognostic Factors.
Dose intensity
The median of the average relative dose intensity calculated for the initial cycles of THP-COPBLM given to all patients was 0.94, ie 50% of the patients received more than 94% of the projected dose rate, whereas 50% of the patients were given less intensive treatment. The median of the relative DI of CPA and THP were 0.95 and 0.93, respectively. All patients received six cycles of chemotherapy which was the full dose for 39 patients and less than the full dose for three patients. The median duration of G-CSF administration was 7 days. G-CSF administration was well tolerated.
Adverse events (Table 2)
Grade 3 or higher adverse events included granulocytopenia in 39 patients (92.9%), and thrombocytopenia in seven (16.7%). Median time of granulocytopenia was 3 days (range 0-10 days). Median time of thrombocytopenia was 5 days (range 0-7 days).
In three patients with a reduced %DLCO, the dose of BLM was reduced in the fifth and sixth cycles. An arrhythmia (уgrade 3) was not found by EKG in any of the patients. The left ventricular ejection fraction assessed by echocardiography showed no change related to chemotherapy in any patients. Fever (у38.0°C) was reported in three patients (7.1%), pneumonia in two (4.7%) and acute bronchitis in one (2.4%). Antibiotics and antifungal agents controlled infection in all patients.
Discussion
The results of trials of third-generation chemotherapy for nonHodgkin's lymphomas (NHL) were reported between the late 1970s and the 1980s. The phase II studies performed in single institutions using MACOP-B, 2 ProMACE-Cyta-BOM 14 and COP-BLAM III 15 achieved CR rates of 70-84% and long-term survival rates of 51-76%. In a study performed by the Southwest Oncology Group (SWOG) and the Eastern Cooperative Oncology Group (ECOG) to compare four chemotherapy regi- Table 2 Adverse events of biweekly THP-COPBLM therapy mens, 3 3-year survival rates were almost the same among the four groups of patients receiving CHOP (54%), m-BACOD (52%), ProMACE-Cyta-BOM (50%) and MACOP-B (50%). Consequently, it was concluded that CHOP, the least lethal chemotherapy regimen, should be the standard chemotherapy for advanced aggressive lymphoma. However, CHOP has not succeeded in improving the CR and long-term survival rates of NHL adequately, particularly in the L-I to H risk groups of IPI. New chemotherapy regimens for NHL need to be developed to attain CR more effectively. DeVita et al 16 described a close association between dose intensity (DI) and survival time. Kwak et al 17 reported a significant correlation between the relative DI of CPA and DXR and the survival period in patients with diffuse large-cell lymphoma.
The use of G-CSF with the CHOP regimen has been increasing the DI in recent years. Usually, doses of key drugs (CPA and DXR) are increased with a reduction of the interval between courses from 3 to 2 weeks. Shipp et al 4 treated patients with advanced NHL and a poor prognosis using CHOP combined with G-CSF, which was administered at 3-week intervals by a dose escalation method or by increasing the doses of CPA and DXR step to the maximum tolerated doses of 4000 mg/m 2 and 70 mg/m 2 , respectively, and achieved a high CR rate of 86%.
In the present study, a CR rate of 88.1% was achieved with a 3-year survival rate of 72.1% and 3-year event-free survival rate of 58% by the biweekly THP-COPBLM regimen given with G-CSF. None of the patients died of adverse events, indicating that this chemotherapy was safe. According to the IPI classification, the CR rates for the L-I, H-I and H risk groups were 94.1, 87.1 and 77.8%, respectively. The rates were relatively high even for the H-I and H risk groups, and were higher than those which we had achieved previously using biweekly COP-BLAM with G-CSF. 1 The increased DI achieved by increasing the dose of CPM from 500 to 750 mg/m 2 and that of VCR from 1.2 to 1.4 mg/m 2 may account for the high efficacy. This suggests that improvement of efficacy depends on how far G-CSF used with cancer chemotherapy can prevent neutropenia and increase the DI. Long-term studies are considered necessary to assess the possible adverse events such as cardiomyopathy, liver dysfunction, as well as neutropenia. In the case of cardiac toxicity, the cumulative dose is critical. Cardiomyopathy should be detected as early as possible because it is an irreversible process. Our previous study on the cardiotoxicity of COP-BLAM showed that cardiac adrenergic abnormalities and impaired mitochondrial function were associated with a cumulative dose of DXR in excess of 400 mg/m. 2, 7 Because DXR was administered at 3-week intervals in the study, however, cardiac toxicity should be assessed with COP-BLAM given at 2-week intervals. In the present study, we used THP which has been reported to be less toxic than DXR. 18 Patients who achieved CR had received three additional courses or a total of 300ෂ450 mg/m 2 of THP without apparent cardiac adrenergic dysfunction or mitochondrial dysfunction. The left ventricular ejection fraction, as assessed by echocardiography, was also not decreased. When THP was used for multi-drug chemotherapy in place of DXR to treat elderly patients with NHL, the modified treatment was less cardiotoxic than the original regimen. 19, 20 Essentially, no studies have been performed, however, to assess the cardiotoxicity of THP in younger patients. Pretreatment cardiac function is not infrequently decreased in elderly patients with NHL. Some elderly patients have a history of angina pectoris or myocardial infarction. Drugs which will not cause acute or subacute adverse cardiac effects seem to be required. Because about 50% of patients with NHL currently achieve long-term survival as a result of progress in treatment, drugs are particularly required to treat younger patients. A long-term follow-up study is also necessary to assess the cardiotoxicity of the biweekly THP-COPBLM regimen used in the present study.
